Research Paper Volume 16, Issue 14 pp 11208—11223
Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway
Figure 2. The expression and prognostic value of CCNL1 in OS. The expression of CCNL1 was overexpressed in low (Huvos 1–2) Huvos grade OS patients *P < 0.05 vs. Huvos 3–4 (A). CCNL1 level was higher in OS tissue **P < 0.01, vs. Osteoblasts (B), and cell lines **P < 0.01, vs. hFOB (C). High CCNL1 level was correlated with worse prognosis in OS in GSE39058 and TARGET cohorts (D, E).